Anavex Life Sciences Corp. (AVXL)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$1.11-11.90%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · AVXL
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Worth watching into the next print: this name operates in a high-miss-rate industry and is a smaller-cap name (higher miss base rate). A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
AVXL — Chair transition
Dated 2026-11-02
Director — Dr. Jiong Ma: The simultaneous resignation of three directors, including the Board Chair, citing misalignment with strategic direction indicates significant internal conflict and governance instability.
Why it matters: The meeting may show whether children can join the Phase 3 Rett study. A clear path would expand the trial plan.
Supportive ifAnavex says the FDA agreed to add children to the Phase 3 Rett study. It reports a clear change to the study plan.
Worry ifAnavex says the FDA did not agree to enroll children, or the meeting was delayed with no new date.
Why it matters: The FDA cleared the study to proceed, but enrollment would show that the program has moved beyond approval to begin.
Supportive ifAnavex says sites are open for its planned Phase 2a Fragile X study. The first participant has enrolled.
Worry ifAnavex reports that the Phase 2a study has not started, or that site or enrollment delays have pushed back its start.
Why it matters: The studies test how the body handles blarcamesine and how it may interact with other drugs. Full results can shape FDA development plans.
Watch forAnavex reports full safety and drug-level results from both studies. It reports no serious safety concerns and says the data support its FDA plan.
Also watch forAnavex reports a serious safety concern, or says the results do not support its FDA plan.
Why it matters: The November 24 report is a near-term check on cash use and program progress. Anavex has named no revenue measure here.
Watch forThe November 24 report shows operating income above zero. It gives clear dates or progress for the Rett and Fragile X studies.
Also watch forThe report shows an operating loss and gives no new dates or clear progress for either study.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$289 on $10,000 · ±2.9% | How much price usually moves either way. |
| Bad day | $837 loss on $10,000 · 8.4% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,474 loss on $10,000 · 84.7% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.